Heart clot showdown: could a simpler blood thinner replace warfarin?
NCT ID NCT07709780
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This trial tests whether apixaban, a newer blood thinner with fixed dosing, works as well as warfarin for dissolving dangerous blood clots in the heart's main pumping chamber. Adults with a confirmed left ventricular thrombus are randomly assigned to receive either apixaban or warfarin for at least three months. The main goal is to see if apixaban is no worse than warfarin at completely clearing the clot, as seen on heart MRI scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apixaban and warfarin
- What this could lead to
- If apixaban works as well as warfarin, it could offer a simpler, safer treatment option for left ventricular thrombus without the need for frequent blood monitoring.
- What could go wrong
- This is a relatively small trial, and apixaban may not prove as effective as warfarin for dissolving the clot. Bleeding risks exist with both drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEFT VENTRICULAR THROMBUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Banner University Medical Center - Tucson
RECRUITINGTucson, Arizona, 85724, United States
Contact
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.